law://au/li/2021/f2021l00800@2026-11-13| Transcatheter mitral valve services | ||
|---|---|---|
| Column 1Item | Column 2Description | Column 3Fee ($) |
| 6082 | Attendance at a TMVr suitability case conference, by a cardiothoracic surgeon or an interventional cardiologist, to coordinate the conference, if:(a) the attendance lasts at least 10 minutes; and(b) the surgeon or cardiologist is accredited by the TMVr accreditation committee to perform the serviceApplicable once each 5 years | 52.95 |
| 6084 | Attendance at a TMVr suitability case conference, by a specialist or consultant physician, other than to coordinate the conference, if the attendance lasts at least 10 minutesApplicable once each 5 years | 39.50 |
| 38461 | TMVr, by transvenous or transeptal techniques, for permanent coaptation of mitral valve leaflets using one or more tissue approximation implants, including intra-operative diagnostic imaging, if:(a) the patient has each of the following risk factors:(i) moderate to severe, or severe, symptomatic degenerative (primary) mitral valve regurgitation (grade 3+ or 4+);(ii) left ventricular ejection fraction of 20% or more;(iii) symptoms of mild, moderate or severe chronic heart failure (New York Heart Association class II, III or IV); and(b) as a result of a TMVr suitability case conference, the patient has been:(i) assessed as having an unacceptably high risk for surgical mitral valve replacement; and(ii) recommended as being suitable for the service; and(c) the service is performed:(i) by a cardiothoracic surgeon, or an interventional cardiologist, accredited by the TMVr accreditation committee to perform the service; and(ii) via transfemoral venous delivery, unless transfemoral venous delivery is contraindicated or not feasible; and(iii) in a hospital that is accredited by the TMVr accreditation committee as a suitable hospital for the service; and(d) a service to which this item, or item 38463, applies has not been provided to the patient in the previous 5 years(H) (Anaes.) (Assist.) | 1,490.25 |
| 38463 | TMVr, by transvenous or transeptal techniques, for permanent coaptation of mitral valve leaflets using one or more Mitraclips™, including intra-operative diagnostic imaging, if:(a) the patient has each of the following risk factors:(i) moderate to severe, or severe, symptomatic functional (secondary) mitral valve regurgitation (grade 3+ or 4+);(ii) left ventricular ejection fraction of 20% to 50%;(iii) left ventricular end systolic diameter of not more than 70mm;(iv) symptoms of mild, moderate or severe chronic heart failure (New York Heart Association class II, III or IV) that persist despite maximally tolerated guideline directed medical therapy; and(b) as a result of a TMVr suitability case conference, the patient has been:(i) assessed as having an unacceptably high risk for surgical mitral valve replacement; and(ii) recommended as being suitable for the service; and(c) the service is performed:(i) by a cardiothoracic surgeon, or an interventional cardiologist, accredited by the TMVr accreditation committee to perform the service; and(ii) via transfemoral venous delivery, unless transfemoral venous delivery is contraindicated or not feasible; and(iii) in a hospital that is accredited by the TMVr accreditation committee as a suitable hospital for the service; and(d) a service to which this item, or item 38461, applies has not been provided to the patient in the previous 5 years(H) (Anaes.) (Assist.) | 1,490.25 |
Sourced from the Federal Register of Legislation at legislation.gov.au, © Commonwealth of Australia, licensed under CC BY 4.0. Compilations may have been reformatted.